Actym Therapeutics’ proprietary STACT™ biological platform is highly modular, multi-faceted and enables cell-, microenvironment-, and tissue-targeted delivery of large, multiplexed plasmid payloads via systemic administration. Expression of payloads, including therapeutic RNA, protein, peptide, and gene editing effectors, can be enabled in either the bacterial vehicle or targeted human cells. Additionally, its engineered auxotrophy allows for tissue-specific localization and enrichment for both oncology and non-oncology indications. Actym’s lead product candidate, ACTM-838, utilizes the STACT™ biological platform to deliver IL-15plex and eSTING payloads directly into the tumor microenvironment, resulting in local engagement of anti-tumor innate and adaptive immunity, while minimizing systemic immune-mediated toxicity.
Read more about this — biospace.com
